NASDAQ:OCUL Ocular Therapeutix Q4 2023 Earnings Report $11.56 +0.13 (+1.09%) As of 03:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Ocular Therapeutix EPS ResultsActual EPS-$0.28Consensus EPS -$0.28Beat/MissMet ExpectationsOne Year Ago EPSN/AOcular Therapeutix Revenue ResultsActual Revenue$14.80 millionExpected Revenue$15.31 millionBeat/MissMissed by -$510.00 thousandYoY Revenue GrowthN/AOcular Therapeutix Announcement DetailsQuarterQ4 2023Date3/11/2024TimeN/AConference Call DateMonday, March 11, 2024Conference Call Time4:00PM ETUpcoming EarningsOcular Therapeutix's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Ocular Therapeutix Earnings HeadlinesH.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy RatingOctober 17, 2025 | msn.comOcular Therapeutix price target raised to $19 from $15 at H.C. WainwrightOctober 8, 2025 | msn.comTrump cannot stop this trainThere are five truths reshaping America’s financial future — and ignoring them could be costly. From an overextended government and vanishing savings to AI-driven job displacement and a widening wealth divide, the warning signs are clear. But according to Porter Stansberry, these same forces are also driving one of the largest wealth transfers in history. His new exposé, The Final Displacement, reveals the economic blueprint behind these shifts — and the final step he believes every American must take to protect and grow their wealth before it’s too late.October 24 at 2:00 AM | Porter & Company (Ad)HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy RecommendationOctober 8, 2025 | msn.comPiper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21October 8, 2025 | finance.yahoo.comOcular Therapeutix™ to Participate in Upcoming Scientific ConferencesOctober 7, 2025 | globenewswire.comSee More Ocular Therapeutix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ocular Therapeutix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocular Therapeutix and other key companies, straight to your email. Email Address About Ocular TherapeutixOcular Therapeutix (NASDAQ:OCUL) is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues. The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S. Food and Drug Administration for the treatment of ocular inflammation following ophthalmic surgery. Ocular Therapeutix also markets ReSure® Sealant, a synthetic polyethylene glycol-based hydrogel approved to seal corneal incisions and reduce postoperative fluid egress. These products exemplify the company’s strategy of combining novel delivery systems with established drug compounds to enhance safety and efficacy. In addition to its marketed therapies, Ocular Therapeutix maintains a pipeline of investigational candidates targeting conditions such as glaucoma and dry eye disease. Key programs include OTX-TKI, a tyrosine kinase inhibitor insert under development for glaucoma, and OTX-DED, an insert incorporating low-dose dexamethasone for chronic dry eye. The company leverages partnerships and licensing agreements to expand its technology platform and advance clinical programs. Led by Chief Executive Officer Antony Mattessich, Ocular Therapeutix operates manufacturing and research facilities in the United States and collaborates with contractors and distributors to support commercialization. The company’s management team combines expertise in ophthalmology, drug delivery, and regulatory affairs to guide product approvals and market access strategies within the U.S. and select international markets.View Ocular Therapeutix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Freeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownTesla’s Earnings Review: Does the Juice Justify the Squeeze?Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideLouis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Upcoming Earnings Cadence Design Systems (10/27/2025)NXP Semiconductors (10/27/2025)Welltower (10/27/2025)Waste Management (10/27/2025)Booking (10/28/2025)Electronic Arts (10/28/2025)Mondelez International (10/28/2025)PayPal (10/28/2025)Regeneron Pharmaceuticals (10/28/2025)Seagate Technology (10/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
